Acute myeloid leukaemia with myelodysplasia-related changes (AML-MRC): Haematopathology module

Hematology (Malignant)Pathology
Written By August Felix

This activity is older than 12 months.

This case has been developed with the assistance of Professor Umberto Gianelli, (Department of Pathophysiology and Transplantation, University of Milan, Italy). This activity was supported by Jazz Pharmaceuticals.

Prescribing information and adverse event reporting information for Vyxeos® Liposomal (44 mg/100 mg powder for concentrate for solution for infusion daunorubicin/cytarabine) can be found here.

For full information on the safety and tolerability profile, please refer to the Summary of Product Characteristics.

This activity is promotional and intended only for healthcare professionals registered to practise in Europe. To proceed, please confirm that you are a healthcare professional practising in Europe.

INT-VYX-2100026 Date of Prep: September 2021

We thank Professor Umberto Gianelli for providing the bone marrow images used in this learning module.

Modules

  • Acute myeloid leukaemia with myelodysplasia-related changes (AML-MRC): Haematopathology module

August Felix
Previous

A 55-year-old man with high-risk polycythaemia vera
Next

Guiding treatment decisions in a premenopausal woman with early-stage invasive breast cancer